{
    "clinical_study": {
        "@rank": "11731", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare pharmacokinetics after single oral administration\n      of candesartan and rosuvastatin each separately versus coadministration of candesartan and\n      rosuvastatin in healthy male volunteers."
        }, 
        "brief_title": "Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers af aged between 20 years to 45 years\n\n          -  Have a weight above 55kg and Ideal body weight (IBW) between -20% and +20% inclusive\n\n          -  Eligible subjects with acceptable medical history and physical examination\n\n        Exclusion Criteria:\n\n        - Have a known hypersensitivity or history of clinically significant hypersensitivity to\n        drugs including the same class drugs with candesartan or rosuvastatin, or other drugs"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079506", 
            "org_study_id": "DP-CTR208-I-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "intervention_name": "Candesartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Candesartan", 
                "Candesartan cilexetil", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jung-gu", 
                    "country": "Korea, Republic of", 
                    "state": "Daejeon", 
                    "zip": "301-721"
                }, 
                "name": "Chungnam National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Candesartan 32 mg and Rosuvastatin 20 mg in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Chungnam National University Hospital", 
            "last_name": "JangHee Hong, PhD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h", 
                "measure": "AUC\u03c4,ss of candesartan", 
                "safety_issue": "No", 
                "time_frame": "22 points"
            }, 
            {
                "description": "0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h", 
                "measure": "Cmax,ss of candesartan", 
                "safety_issue": "No", 
                "time_frame": "22 points"
            }, 
            {
                "description": "0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h", 
                "measure": "AUC\u03c4,ss of rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 points"
            }, 
            {
                "description": "0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h", 
                "measure": "Cmax,ss of rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 points"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079506"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h", 
                "measure": "tmax,ss of candesartan", 
                "safety_issue": "No", 
                "time_frame": "22 points"
            }, 
            {
                "description": "0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h", 
                "measure": "CLss/F of candesartan", 
                "safety_issue": "No", 
                "time_frame": "22 points"
            }, 
            {
                "description": "0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h", 
                "measure": "Cmin,ss of candesartan", 
                "safety_issue": "No", 
                "time_frame": "22 points"
            }, 
            {
                "description": "0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h", 
                "measure": "tmax,ss of rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 points"
            }, 
            {
                "description": "0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h", 
                "measure": "CLss/F of rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 points"
            }, 
            {
                "description": "0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h", 
                "measure": "Cmin,ss of rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 points"
            }
        ], 
        "source": "DreamPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DreamPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}